El Tor is a biotype of the bacterium Vibrio cholerae serogroup O1, the primary causative agent of epidemic cholera, distinguished from the classical biotype by specific phenotypic traits such as resistance to polymyxin B, hemolysis on sheep blood agar, and a positive Voges-Proskauer reaction.[1] Named after the El Tor quarantine station on Egypt's Sinai Peninsula, where it was first isolated in 1905 from Indian pilgrims who died from a paratyphoid-like illness, the strain was initially considered non-pathogenic or mildly virulent.[2] However, El Tor gained prominence as the etiological agent of the seventh cholera pandemic, which began in 1961 on the Indonesian island of Sulawesi and has since spread to over 100 countries, causing millions of cases and continuing to drive global cholera outbreaks as of 2025.[3][4][5]Compared to the classical biotype, which fueled the first six cholera pandemics from 1817 to 1961, El Tor strains exhibit greater environmental resilience, including longer survival in aquatic environments and higher acid tolerance, enabling more efficient transmission through contaminated water and food.[6][7] These characteristics contribute to El Tor's higher infectivity and ability to establish asymptomatic carriers, who can spread the disease over extended periods.[8] Within the El Tor biotype, strains are further subdivided into serotypes Ogawa and Inaba (with rare Hikojima), and many modern variants carry hybrid genetic elements, such as the classical cholera toxin (ctxB) gene, enhancing their virulence and altering clinical severity.[9][10]The ongoing dominance of El Tor in cholera epidemiology underscores its evolutionary adaptability, with genomic analyses revealing ongoing mutations and recombination events that have produced altered variants responsible for major outbreaks in regions like Asia, Africa, and the Americas.[11][12] Despite advances in vaccination, sanitation, and rehydration therapy, El Tor remains a significant public health threat, particularly in areas with poor water infrastructure, prompting continued surveillance by organizations like the World Health Organization.[13]
Biological Characteristics
Taxonomy and Morphology
El Tor is classified as a biotype of Vibrio cholerae within the serogroup O1, a Gram-negative bacterium belonging to the family Vibrionaceae. The O1 serogroup encompasses three main serotypes—Ogawa, Inaba, and the rarer Hikojima—distinguished by variations in their lipopolysaccharide (LPS) O-antigen structure, with Ogawa expressing the A antigen, Inaba the C antigen, and Hikojima both.[9][14] This biotype differs phenotypically from the classical biotype of V. cholerae O1, reflecting adaptations that enhance environmental persistence.[8]Morphologically, El Tor strains appear as comma-shaped or slightly curved bacilli, typically measuring 1.5–4.0 μm in length and 0.2–0.4 μm in width, and are motile due to a single polar flagellum that enables chemotaxis.[8] These bacteria are facultatively anaerobic and exhibit rapid growth, with a generation time under 30 minutes in nutrient-rich media. Optimal growth occurs at 37°C, the human body temperature, and in alkaline environments with a pH range of 8.5–9.5, where they thrive better than in acidic conditions below pH 6.0.[8][15]Key phenotypic markers distinguish El Tor from other biotypes, including positive hemolysin production, observed as a zone of hemolysis on sheep bloodagar due to the El Tor-specific hemolysin (El Tor HlyA).[8] Strains are Voges-Proskauer positive, indicating acetoin production from glucose fermentation, and resistant to polymyxin B at concentrations up to 50 units per disk, unlike the sensitive classical biotype.[8] Additionally, El Tor exhibits mannose-resistant hemagglutination and agglutination of chicken erythrocytes, a trait linked to its surface adhesins.[16] These markers are routinely used in laboratory identification protocols.[17]El Tor demonstrates notable environmental resilience, capable of surviving in saline and brackish waters with salinities of 0.25–3.0%, often associating with plankton and copepods for protection.[18] It readily forms biofilms on abiotic surfaces and biotic hosts, enhancing survival under nutrient-limited or stressful conditions through extracellular matrix production involving polysaccharides like VPS and EPS.[19] This biofilm-forming ability contributes to its persistence in aquatic ecosystems, facilitating long-term viability outside human hosts.[20]
Genetic Features
The genome of Vibrio cholerae O1 El Tor consists of two circular chromosomes: a large chromosome of 2,961,146 base pairs and a small chromosome of 1,072,314 base pairs, encoding a total of 3,885 open reading frames.[21] The cholera toxin genes ctxA and ctxB are located on the CTXφ prophage, a filamentous bacteriophage integrated into the large chromosome at the dif site.[22] The El Tor-specific ctxB allele differs from that of the classical biotype by two amino acid substitutions at positions 39 and 68 (tyrosine at position 39 instead of histidine, and isoleucine at position 68 instead of threonine), resulting from three nucleotide polymorphisms that influence toxin structure and immunogenicity.[12][23]Distinct genetic markers define the El Tor biotype, including the rstR gene on the CTXφ phage, which encodes a repressor protein that regulates phage transcription and excision via interaction with the activator RstA.[24] The Vibrio pathogenicity island-1 (VPI-1), a 39.8 kb genomic island on the large chromosome, harbors genes for the toxin-coregulated pilus (TCP), such as tcpA, essential for intestinal colonization.[25] Additionally, the hlyA gene on the small chromosome encodes the El Tor-specific hemolysin, a 65 kDa pore-forming toxin contributing to the biotype's environmental persistence.[26][27]Evolutionary adaptations in El Tor strains include the emergence of hybrid variants since the mid-1990s, where seventh pandemic El Tor backbones acquired classical-like ctxB alleles (e.g., ctxB1 or ctxB7), enhancing virulence while retaining El Tor fitness traits.[28] Recent genomic analyses have identified antibiotic resistance genes such as bla<sub>PER-7</sub>, conferring extended-spectrum beta-lactamase activity, in multidrug-resistant isolates from 2025 outbreaks.[29]Carbapenem resistance, mediated by carbapenemase genes like bla<sub>NDM-1</sub>, has appeared in 2024–2025 clinical isolates of El Tor variants, marking a shift toward pan-drug resistance.[30]Serotype shifts, such as reversion from Inaba to Ogawa via mutations in the wbeT gene, have been observed in African lineages like AFR12, driven by immune selection.[31]Genomic surveillance of the seventh pandemic reveals multiple independent introductions of El Tor lineages into regions like Africa and the Middle East since 1965, with at least 11 distinct waves into Africa since 1970.[32] These introductions have led to clonal expansions through selective sweeps, where advantageous mutations (e.g., in virulence regulators or resistance loci) enable rapid dissemination and dominance of specific sublineages, as evidenced by whole-genome sequencing of over 1,000 isolates.[32]
Historical Development
Discovery and Initial Isolation
The El Tor biotype of Vibrio cholerae was first isolated in 1905 by German physician Felix Gotschlich at the El Tor quarantine station on the Sinai Peninsula in Egypt. This station, established to monitor pilgrims returning from Mecca via the Red Sea route, reported cases of mild diarrheal illness among Indonesian pilgrims, distinct from severe cholera. Gotschlich isolated the hemolytic vibrios from stool samples of affected individuals, noting their similarity to cholera-causing bacteria but association with less severe symptoms, such as paratyphoid-like fever rather than acute dehydration.[2][33]Initial observations highlighted the vibrios' link to asymptomatic carriers among pilgrims, with isolations often from individuals showing no overt cholera signs, complicating their recognition as pathogenic. These strains were hemolytic on sheep blood agar, a trait absent in classical V. cholerae, and exhibited variable agglutination with classical cholera antisera, leading to early confusion in laboratory identification. Consequently, the isolates were initially considered non-pathogenic variants of V. cholerae due to the mild clinical presentations and biochemical discrepancies.[8][2]By the mid-20th century, further isolations prompted debate over their taxonomy, with some researchers, including Robert Pollitzer in 1959, proposing V. eltor as a separate species based on hemolytic activity and resistance to certain bacteriophages. However, in 1965, R. Hugh reclassified El Tor as a biotype of V. cholerae through systematic biochemical testing of over 200 strains, emphasizing differences in Voges-Proskauer reaction, chicken cell agglutination, and hemolysis while confirming shared core traits like oxidase positivity and sucrosefermentation.[34]Prior to 1961, El Tor strains were sporadically detected in Southeast Asia, such as in Indonesia and the Philippines, and the Middle East, primarily from pilgrim carriers or isolated mild cases, without triggering epidemics. These detections, often during routine surveillance at quarantine sites, underscored the biotype's circulation in endemic areas but its limited epidemic potential at the time.[35][36]
Role in Cholera Pandemics
The seventh cholera pandemic, driven by Vibrio cholerae O1 biotype El Tor, originated in 1961 on Sulawesi Island, Indonesia.[37] From there, it rapidly disseminated across Asia, reaching East Pakistan (present-day Bangladesh) by 1963–1964 and other regions of the continent soon after.[38] By the 1970s, the strain had spread to Africa, marking the continent's entry into the pandemic era, and continued its global expansion, arriving in Latin America in 1991 and establishing endemicity worldwide by the mid-1990s.[38][11]Several biological attributes of El Tor contributed to its persistence and widespread transmission during the pandemic. Unlike the classical biotype, El Tor exhibits a higher proportion of asymptomatic carriers, with ratios of up to 50:1 relative to symptomatic cases, facilitating silent spread.[39] The incubation period for El Tor cholera is typically a few hours to 5 days (median ~1–2 days), similar to the classical biotype; however, El Tor's higher rate of asymptomatic carriers facilitates prolonged transmission.[40] Additionally, El Tor demonstrates superior environmental resilience, including enhanced survival in aquatic reservoirs and competitive growth advantages over classical strains in nutrient-limited conditions.[41][6]Throughout the pandemic, El Tor underwent notable evolutionary changes, transitioning toward hybrid forms that combined traits from both biotypes. In the 1990s, variants emerged in Bangladesh, such as the Matlab strains isolated between 1991 and 1994, which incorporated classical cholera toxin genes (ctxB) into an El Tor genetic backbone, enhancing virulence.[42] A significant derivative, V. cholerae O139, arose in 1992 as an El Tor offshoot through acquisition of novel surface polysaccharide genes, briefly causing outbreaks in South Asia before declining.[43] More recently, in 2024–2025, genomic analyses have identified clonal expansions of El Tor lineages, including the AFR15 sublineage in southern Africa and repeated introductions from South Asia driving surges in both regions.The rise of El Tor corresponded with the decline of the classical biotype, achieving dominance in cholera cases globally by the 1960s.[44] Classical strains were progressively displaced and have not been isolated from clinical cases since the 1980s, rendering them effectively extinct in the pandemic context.[45]
Pathogenic Mechanisms
Virulence Factors
The primary virulence factor of the El Tor biotype of Vibrio cholerae O1 is cholera toxin (CT), an AB5 enterotoxin responsible for the massive secretory diarrhea characteristic of cholera. CT consists of one enzymatic A subunit (encoded by ctxA) and five binding B subunits (encoded by ctxB), forming a heterohexameric structure that binds to GM1 gangliosides on intestinal epithelial cells, allowing the A subunit to ADP-ribosylate Gsα proteins and dysregulate cyclic AMP levels. The ctxAB genes are carried on the CTXΦ filamentous bacteriophage integrated into the bacterial chromosome.[46][47]In the El Tor biotype, the ctxB allele (designated ctxB3) differs from the classical biotype's ctxB1 by two amino acid substitutions (tyrosine at position 39 and isoleucine at position 68). Prototype El Tor strains with ctxB3 produce less CT than classical strains under certain conditions, but the biotype's overall epidemic potential is enhanced by other traits. The Haitian variant of El Tor carries ctxB7, with additional mutations leading to altered CT properties. Hybrid El Tor strains, which have acquired the classical ctxB1 through phage recombination, exhibit enhanced CT potency and greater clinical severity, as observed in outbreaks across Asia and Africa since the early 2000s.[48][10]Another essential virulence factor is the toxin-coregulated pilus (TCP), a type IV bundle-forming pilus that mediates adherence to intestinal epithelium and is crucial for initial colonization. TCP is encoded by the tcpA structural gene and accessory genes (tcpB through tcpQ) within the 40 kb Vibrio pathogenicity island-1 (VPI-1), a mobile element that also serves as the receptor for CTXΦ phage infection. Expression of TCP is coregulated with CT via the ToxR/ToxT regulatory cascade, activated by environmental cues like low pH and bile.[49][50]El Tor strains produce additional accessory virulence factors that enhance pathogenesis and survival. The RTX (repeats-in-toxin) family hemolysin, encoded by hlyA (also known as vchA in some variants), is a pore-forming cytolysin that lyses eukaryotic cells, including erythrocytes and intestinal epithelia, promoting nutrient release and tissuedamage.[51] The accessory cholera enterotoxin (ACE), encoded by ace on the VPI-1 island, is a minor enterotoxin that induces fluid secretion and may synergize with CT. Zonula occludens toxin (ZOT), encoded by zot adjacent to ctxAB on CTXΦ, disrupts intestinal tight junctions by protein kinase C-mediated signaling, potentially facilitating paracellular toxin passage.[46]Multidrug efflux pumps, such as those from the resistance-nodulation-division (RND) family (e.g., VexAB, VexCD, and VexGH), contribute to virulence by conferring resistance to antimicrobial compounds, including bile salts and host-derived stresses, while also influencing optimal production of CT and TCP. These pumps export a broad range of substrates, enhancing El Tor's survival in the host intestine and environment. Genomic analyses of recent isolates (as of 2024) indicate that mobile genetic elements, such as integrons and plasmids, have amplified efflux-mediated resistance in circulating El Tor hybrids. Recent 2025 studies have identified carbapenem-resistant El Tor variants with enhanced mobile genetic elements conferring broad-spectrum resistance, further complicating outbreak control.[52][53][54]
Infection and Host Interaction
Vibrio cholerae biotype El Tor is primarily transmitted through the fecal-oral route, with contaminated water and food serving as the main vehicles for infection.[55] This strain exhibits a notably low infectious dose, ranging from 10³ to 10⁶ colony-forming units (CFU), which is facilitated by its enhanced acid tolerance compared to earlier biotypes.[56] The acid tolerance response (ATR) enables survival in the acidic gastric environment through mechanisms involving outer membrane porin OmpU, the CadC regulator, and the lysine decarboxylase CadA, often aided by protective mucus layers.[57] Once past the stomach, the bacteria reach the small intestine, where they initiate colonization.Colonization by El Tor involves the toxin-coregulated pilus (TCP), a key adhesin that mediates attachment to the epithelial cells of the small intestine and promotes the formation of microcolonies.[58] These microcolonies evolve into protective biofilms on mucosal surfaces, supported by exopolysaccharide production and quorum sensing, which shield the bacteria from host defenses and peristalsis.[58] The core pathophysiology stems from the action of cholera toxin (CT), which enters host cells and ADP-ribosylates Gsα, leading to sustained activation of adenylate cyclase and elevated cyclic AMP (cAMP) levels.[59] This elevation opens the cystic fibrosis transmembrane conductance regulator (CFTR) channel, causing massive chloride (Cl⁻) secretion into the intestinal lumen, followed by sodium and water efflux, resulting in the characteristic profuse watery diarrhea known as "rice-water" stool.[59]In contrast to the classical biotype, El Tor demonstrates prolonged gut persistence, with viable bacteria detectable for up to two weeks post-infection in animal models versus only a few days for classical strains, enhancing its transmissibility.[60] This extended residence contributes to higher rates of asymptomatic carriage, observed in approximately 60-75% of infections.[61] El Tor evades robust immune responses partly through weaker induction of secretory IgA compared to classical strains and by deploying multifunctional autoprocessing repeats-in-toxin (MARTX) to suppress innate immunity, inhibiting neutrophil recruitment via outer membrane vesicles.[62] Additionally, rare chronic carriers, such as the documented case of "Cholera Dolores" who harbored El Tor for nearly 10 years following initial infection in the 1960s, underscore the strain's potential for long-term host persistence without secondary transmission.[63]
Epidemiological Profile
Transmission Dynamics
The primary mode of transmission for Vibrio cholerae O1 El Tor is waterborne, facilitated by the bacterium's halophilic nature, which allows it to thrive and persist in brackish and estuarine environments with moderate salinity. This adaptation enables El Tor strains to survive in coastal and riverine waters, such as those in the Gulf of Mexico, where they have been endemic and linked to sporadic human cases through contaminated seafood or water sources. Poor sanitation infrastructure amplifies this transmission, as fecal contamination of drinking water sources directly introduces the pathogen into human populations, with outbreaks often exploding in areas lacking adequate sewage treatment.[64][65]Human mobility plays a critical role in seeding and propagating El Tor outbreaks, particularly through large-scale gatherings like pilgrimages and migration patterns that facilitate inter-regional spread. For instance, human mobility, including pilgrimages, has historically played a role in El Tor spread, with the seventh pandemic disseminating from Indonesia in 1961 through regional travel and trade to the Middle East and beyond. In naive populations without prior immunity, El Tor exhibits a high basic reproduction number (R0) estimated between 2 and 5, reflecting its potential to generate multiple secondary infections per case, especially under conditions of overcrowding and inadequate hygiene.[35][66]Environmental drivers significantly influence El Tor's transmission dynamics, with climate change exacerbating risks through altered hydrological cycles that promote bacterial proliferation. Associations with zooplankton, particularly copepods like Acartia tonsa and Eurytemora affinis, enhance oceanic persistence by providing protective niches where El Tor can form biofilms and survive adverse conditions, facilitating long-distance dispersal via water currents. Recent upsurges from 2021 to 2025, including over 535,000 reported cases in 2023 across 45 countries, have been linked to extreme weather events such as flooding and El Niño-induced anomalies, which contaminate water supplies and disrupt sanitation systems in vulnerable regions.[67][64][68]Asymptomatic carriers constitute 50-75% of El Tor infections, enabling silent transmission as these individuals shed viable bacteria in feces for up to 1-10 days, often without detection or intervention. This prolonged excretion period, averaging longer in El Tor compared to classical biotypes, sustains environmental reservoirs and contributes to the strain's epidemic potential by allowing undetected circulation within communities.[69][70]
Global Distribution and Recent Outbreaks
El Tor strains of Vibrio cholerae O1 are endemic in South Asia, particularly Bangladesh and India, where they persist in aquatic environments like the Ganges Delta and Bay of Bengal, contributing to seasonal outbreaks linked to monsoon flooding and poor sanitation.[71] In sub-Saharan Africa, these strains maintain endemicity across multiple countries, including the Democratic Republic of the Congo and Nigeria, fueled by ongoing environmental reservoirs and humanitarian crises.[64] Haiti remains a key endemic focus in the Americas following the 2010 introduction, with persistent circulation despite vaccination efforts.[72] Post-1991, after the initial Latin American epidemic wave, El Tor cholera has occurred sporadically in the region, often tied to imported cases or localized water contamination rather than sustained endemic transmission.[73]The seventh cholera pandemic, driven predominantly by El Tor variants, persisted with an estimated 1.3 to 4.0 million global cases annually before 2020, underscoring its entrenched global footprint despite control measures.[64] From 2021 to 2025, a marked surge occurred, with over 500,000 reported cases in Africa alone during this period, exacerbated by conflict, displacement, and climate variability; for instance, the 2023–2024 outbreak in Malawi and Zambia registered tens of thousands of cases, peaking with Malawi's 59,325 confirmed infections and 1,774 deaths by early 2024.[64] This uptick reflects broader trends, including approximately 734,000 global cases in 2024 and approximately 546,200 through mid-October 2025, with Africa bearing the heaviest burden through multi-country epidemics in 23 nations. In 2025, Sudan reported over 120,000 cases and 3,368 deaths as of October, highlighting impacts of conflict and displacement.[74][75][76]Recent developments highlight evolving threats from El Tor strains, including the emergence of drug-resistant clones; in 2024–2025, isolates harboring the blaPER-7 gene, conferring resistance to multiple antibiotics, were detected in travelers returning to the United Kingdom from endemic areas, signaling potential for wider dissemination via international mobility.[77] Similarly, carbapenem-resistant El Tor variants carrying the blaNDM-1 gene on transferable plasmids were identified in Gujarat, India, among clinical cholera patients in 2019–2025 samples, raising alarms for treatment challenges in high-burden settings.[78] Climate-amplified events have also intensified transmission, as seen in Cameroon's 2022–2024 outbreaks, where genomic analysis revealed convergent reversion to the Ogawa serotype within the AFR12 sublineage of El Tor, linked to heavy rainfall and flooding that expanded environmental reservoirs.[79] Multiple introductions via human migration continue to drive regional spread, with genomic surveillance tracing transcontinental lineages from Asia to Africa, facilitating repeated seeding of local epidemics.[80]Surveillance gaps exacerbate the challenge of tracking El Tor cholera, with underreporting in endemic areas estimated to capture only 11–46% of actual cases in Africa due to weak integrated disease surveillance systems, limited laboratory capacity, and data politicization.[81] Genomic tracking efforts reveal ongoing diversification of African El Tor lineages, such as the AFR12 sublineage, through multicountry sequencing of over 700 isolates from 2019–2024, which underscores the need for enhanced regional networks to monitor evolutionary changes and importation events.
Clinical and Public Health Aspects
Disease Manifestation and Diagnosis
Infection with the El Tor biotype of Vibrio cholerae O1 typically manifests as cholera, characterized by the sudden onset of profuse watery diarrhea, often described as "rice-water" stools due to their pale, flecked appearance, accompanied by vomiting and rapid dehydration. Leg cramps and sunken eyes may occur as dehydration progresses, but fever is usually absent. The incubation period ranges from a few hours to 5 days, most commonly 1 to 3 days.[82][83][84]Compared to the classical biotype, El Tor infections are generally milder, with a higher proportion of cases remaining asymptomatic or presenting as mild gastroenteritis, and a lower case-fatality rate of less than 1% with prompt rehydration therapy (versus approximately 50% for untreated severe cholera cases, for both biotypes). The illness duration is typically 3 to 7 days in uncomplicated cases, though severe dehydration can lead to hypovolemic shock and death within hours if untreated. Certain hybrid El Tor variants, which incorporate the classical biotype's cholera toxin subunit B (ctxB) gene, can cause more severe, classical-like symptoms with higher stool volumes and greater clinical severity. Recent outbreaks in 2024–2025 have involved highly drug-resistant El Tor strains, potentially complicating management and increasing risks of severe outcomes in resource-limited settings. As of August 2025, the World Health Organization reported 409,222 cholera cases and 4,738 deaths across 31 countries, predominantly in Africa (e.g., Democratic Republic of the Congo, Sudan), underscoring the persistent burden of El Tor strains.[82][85][86][87]Diagnosis of El Tor cholera relies on clinical suspicion in endemic areas or during outbreaks, followed by laboratory confirmation. Stool specimens are cultured on selective media such as thiosulfate-citrate-bile salts-sucrose (TCBS) agar, where V. cholerae O1 appears as yellow colonies due to sucrose fermentation. Rapid diagnostic tests (RDTs) detect the O1 lipopolysaccharideantigen directly from stool, offering results within 15–30 minutes for field use. Molecular methods, including PCR targeting the cholera toxin genes ctxA and ctxB, provide high sensitivity and specificity, while multiplex assays can simultaneously detect biotype-specific markers such as the El Tor variants of tcpA (TCP pilus) and hlyA (hemolysin). Biotyping distinguishes El Tor from classical strains via phenotypic tests: positive Voges-Proskauer reaction, hemolysis on sheep blood agar, and resistance to phage IV.[17][88][84]Differential diagnosis includes other causes of acute watery diarrhea, such as enterotoxigenic Escherichia coli (ETEC), which produces similar enterotoxins but typically causes less voluminous stools and slower dehydration without the characteristic rice-water appearance. Laboratory culture and PCR differentiate V. cholerae from ETEC by identifying species-specific genes and the hemolytic activity unique to El Tor strains, aiding rapid distinction in mixed outbreaks.[89][90][91]
Treatment, Prevention, and Control
The cornerstone of treatment for cholera caused by the El Tor strain of Vibrio cholerae O1 is prompt rehydration to replace fluids and electrolytes lost through severe diarrhea. Oral rehydration solution (ORS) is the primary therapy for most cases, including mild to moderate dehydration, and can be administered at home or in outpatient settings when patients can tolerate oral intake. For severe dehydration, intravenous fluids such as Ringer's lactate are initiated immediately, followed by ORS once the patient stabilizes.[64][92]Antibiotics are recommended as adjunctive therapy in severe cases to reduce the duration and volume of diarrhea, shorten the period of bacterial excretion, and minimize transmission risk. Preferred options include a single 300 mg dose of doxycycline for adults and children over 12 years, or azithromycin (1 g single dose for adults; 20 mg/kg for children) for younger children, pregnant women, or in areas with tetracyclineresistance. However, emerging antimicrobial resistance complicates these choices; for instance, El Tor strains in Africa have shown high-level resistance to ciprofloxacin since 2024, with multidrug-resistant variants spreading across the continent and limiting fluoroquinolone use.[93][86][94]For children aged 6 months to 5 years with suspected cholera, zinc supplementation is advised alongside rehydration and antibiotics to reduce the duration and severity of diarrhea. The World Health Organization recommends 20 mg of elemental zinc daily for 10–14 days (10 mg for infants under 6 months), which has been shown to decrease stool output and hospitalization needs in pediatric cholera cases.[95][96]Prevention of El Tor cholera relies heavily on improving water, sanitation, and hygiene (WASH) infrastructure to interrupt fecal-oral transmission. Key measures include access to safe drinking water through chlorination or boiling, proper sanitation facilities to prevent contamination, and handwashing with soap, particularly in endemic areas and during outbreaks. These interventions can reduce cholera incidence by up to 90% in high-risk communities when implemented comprehensively.[64]Oral choleravaccines (OCVs) provide an additional layer of protection, particularly in endemic settings and for at-risk travelers. WHO-prequalified vaccines such as Dukoral (recombinant B subunit–whole cell) and Shanchol (bivalent whole-cell) offer 65–85% efficacy against El Tor O1 strains for 2–5 years after two doses, with single-dose regimens providing shorter-term protection (around 59–79% for 6–12 months). These vaccines are recommended by the CDC and WHO for individuals aged 2 years and older traveling to cholera-affected areas or residing in high-burden regions, though they are not a substitute for WASH measures.[97][98][99]Control of El Tor cholera outbreaks involves integrated public health strategies coordinated by networks like the Global Task Force on Cholera Control (GTFCC). Enhanced surveillance systems, including rapid reporting of suspected cases and laboratory confirmation via culture or PCR, enable early detection and response. Contact tracing identifies and treats exposed individuals, while ring vaccination deploys OCV stockpiles around outbreak foci to contain spread, as demonstrated in Guinea where Shanchol reduced cases by 86% in vaccinated clusters. Early warning systems incorporating climate data, such as rainfall patterns that exacerbate transmission, support predictive modeling and preemptive interventions in vulnerable areas.[100][101][102]Persistent challenges hinder effective management of El Tor cholera, including low OCV coverage—often below 50% in high-burden countries due to supply constraints, logistical barriers, and funding gaps—which limits outbreak containment. Antimicrobial stewardship is critical to preserve antibiotic efficacy amid rising resistance in variants like those harboring blaPER-7 genes, necessitating tailored susceptibility testing and alternative therapies. Ongoing GTFCC efforts aim to address these through expanded vaccine stockpiles and integrated WASH-vaccination campaigns.[103][29][93]